AJANTPHARM vs LUPIN: Stock Comparison
LUPIN is the larger company by market capitalisation. AJANTA PHARMA shows a higher dividend yield, lower leverage and a higher net margin, while LUPIN shows a lower P/E, a higher ROE and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
AJANTPHARM leads 4; LUPIN leads 9 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | AJANTPHARM | LUPIN |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | AJANTPHARM | LUPIN |
|---|---|---|
| Live Price | ₹3,533.4 | ₹2,095 |
| Day Change | 0.38% | 0.83% |
| Volume | 45,547 | 6.22 L |
| 52-Week High | ₹3,796 | ₹2,529.5 |
| 52-Week Low | ₹2,329.9 | ₹1,900 |
| Distance from 52W High | -6.92% | -17.18% |
Valuation
| Metric | AJANTPHARM | LUPIN |
|---|---|---|
| Market Cap | ₹44,190 Cr | ₹95,836 Cr |
| P/E Ratio | 38.94x | 17.33x |
| P/B Ratio | 9.76x | 4.27x |
| EPS | ₹26.75 | ₹59.37 |
| Book Value | ₹362.35 | ₹492.38 |
| Dividend Yield | 1.7% | 0.86% |
Growth
| Metric | AJANTPHARM | LUPIN |
|---|---|---|
| Revenue Growth (TTM YoY) | 21.5% | 31.9% |
| EPS Growth (TTM YoY) | 18.6% | 89% |
| Qtr Sales Growth | 9.22% | -13.35% |
| Qtr Profit Growth | 5.94% | 91.58% |
Profitability & Leverage
| Metric | AJANTPHARM | LUPIN |
|---|---|---|
| ROE | 23.33% | 23.79% |
| ROCE | 23.05% | 23.47% |
| Net Margin | 19.38% | 17.65% |
| Operating Margin | 25.56% | 26.14% |
| Debt to Equity | 0.05x | 0.26x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | AJANTPHARM | LUPIN |
|---|---|---|
| Promoter Holding | 63.48%▼ 2.77 pp | 46.57% |
| FII Holding | 7.68%▼ 0.58 pp | 22.42%▲ 0.71 pp |
| DII Holding | 21.8%▲ 3.43 pp | 24.65%▼ 0.67 pp |
| Public Holding | 7.03%▼ 0.09 pp | 6.08%▼ 0.03 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: AJANTA PHARMA and LUPIN.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.